Literature DB >> 17786385

High-resolution SNP and haplotype maps of the human gamma-glutamyl carboxylase gene (GGCX) and association study between polymorphisms in GGCX and the warfarin maintenance dose requirement of the Japanese population.

Pei-Chieng Cha1, Taisei Mushiroda2, Atsushi Takahashi3, Shigeru Saito4, Hideki Shimomura4, Takao Suzuki4, Naoyuki Kamatani3, Yusuke Nakamura5,6.   

Abstract

Gamma-glutamyl carboxylase (GGCX) plays an important role in blood coagulation through post-translational carboxylation of vitamin K-dependent blood-clotting proteins. This carboxylation process is impaired in the presence of warfarin, a vitamin K antagonist. Recent studies on GGCX have provided insights into association of polymorphisms in this gene, with inter-individual differences in the required warfarin maintenance dose. In order to provide a useful resource for further elucidating this association, we here report a high-resolution single nucleotide polymorphism (SNP) and haplotype maps of an 18-kb genomic region corresponding to the GGCX locus in the Japanese population. Among 41 SNPs, seven insertion/deletion polymorphisms, and a microsatellite polymorphism that we detected by direct sequencing of the DNAs of 96 Japanese individuals who were treated with warfarin, 32 genetic variations have not been reported. Using genotype information from 12 SNPs and the EM algorithm, we estimated haplotypes for this genomic region. Subsequently, we investigated associations of each of these polymorphisms with the warfarin maintenance-dose requirements of 828 Japanese patients, including the 96 patients that were used for DNA sequencing. We found no significant association between the polymorphisms in GGCX and the dose requirement.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17786385     DOI: 10.1007/s10038-007-0183-9

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  23 in total

Review 1.  Pharmacogenetics of oral anticoagulants.

Authors:  Ann K Daly; Barry P King
Journal:  Pharmacogenetics       Date:  2003-05

2.  Cloning and expression of the cDNA for human gamma-glutamyl carboxylase.

Authors:  S M Wu; W F Cheung; D Frazier; D W Stafford
Journal:  Science       Date:  1991-12-13       Impact factor: 47.728

Review 3.  Molecular basis of vitamin K-dependent gamma-carboxylation.

Authors:  B Furie; B C Furie
Journal:  Blood       Date:  1990-05-01       Impact factor: 22.113

4.  Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.

Authors:  Rina Kimura; Kotaro Miyashita; Yoshihiro Kokubo; Yasuhisa Akaiwa; Ryoichi Otsubo; Kazuyuki Nagatsuka; Toshiho Otsuki; Akira Okayama; Kazuo Minematsu; Hiroaki Naritomi; Shigenori Honda; Hitonobu Tomoike; Toshiyuki Miyata
Journal:  Thromb Res       Date:  2006-10-17       Impact factor: 3.944

Review 5.  Vitamin K-dependent carboxylase.

Authors:  J W Suttie
Journal:  Annu Rev Biochem       Date:  1985       Impact factor: 23.643

6.  Common VKORC1 and GGCX polymorphisms associated with warfarin dose.

Authors:  M Wadelius; L Y Chen; K Downes; J Ghori; S Hunt; N Eriksson; O Wallerman; H Melhus; C Wadelius; D Bentley; P Deloukas
Journal:  Pharmacogenomics J       Date:  2005       Impact factor: 3.550

7.  The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement.

Authors:  Darja Herman; Polona Peternel; Mojca Stegnar; Katja Breskvar; Vita Dolzan
Journal:  Thromb Haemost       Date:  2006-05       Impact factor: 5.249

8.  Gamma-glutamyl carboxylase (GGCX) microsatellite and warfarin dosing.

Authors:  Leslie Y Chen; Niclas Eriksson; Rhian Gwilliam; David Bentley; Panos Deloukas; Mia Wadelius
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

Review 9.  Warfarin therapy: evolving strategies in anticoagulation.

Authors:  J D Horton; B M Bushwick
Journal:  Am Fam Physician       Date:  1999-02-01       Impact factor: 3.292

10.  Identification of the gene for vitamin K epoxide reductase.

Authors:  Tao Li; Chun-Yun Chang; Da-Yun Jin; Pen-Jen Lin; Anastasia Khvorova; Darrel W Stafford
Journal:  Nature       Date:  2004-02-05       Impact factor: 49.962

View more
  9 in total

Review 1.  Pharmacogenetics of warfarin: challenges and opportunities.

Authors:  Ming Ta Michael Lee; Teri E Klein
Journal:  J Hum Genet       Date:  2013-05-09       Impact factor: 3.172

2.  Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU.

Authors:  Stuart A Scott; Manishkumar Patel; Suparna Martis; Steven A Lubitz; Sarina van der Zee; Chang Yoo; Lisa Edelmann; Jonathan L Halperin; Robert J Desnick
Journal:  Pharmacogenomics       Date:  2011-12-21       Impact factor: 2.533

3.  Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans.

Authors:  Larisa H Cavallari; Minoli Perera; Mia Wadelius; Panos Deloukas; Gelson Taube; Shitalben R Patel; Keston Aquino-Michaels; Marlos A G Viana; Nancy L Shapiro; Edith A Nutescu
Journal:  Pharmacogenet Genomics       Date:  2012-02       Impact factor: 2.089

Review 4.  Pharmacogenomics: the genetics of variable drug responses.

Authors:  Dan M Roden; Russell A Wilke; Heyo K Kroemer; C Michael Stein
Journal:  Circulation       Date:  2011-04-19       Impact factor: 29.690

Review 5.  Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?

Authors:  Mohamed H A Shahin; Julie A Johnson
Journal:  Curr Opin Cardiol       Date:  2013-05       Impact factor: 2.161

Review 6.  Warfarin Pharmacogenetics: New Life for an Old Drug.

Authors:  Ming-Shien Wen; Ming Ta Michael Lee
Journal:  Acta Cardiol Sin       Date:  2013-05       Impact factor: 2.672

Review 7.  Association of genetic polymorphisms with warfarin dose requirements in Chinese patients.

Authors:  Yundan Liang; Zhiyu Chen; Gang Guo; Xuemei Dong; Chunting Wu; He Li; Tong Wang; Bingying Xu
Journal:  Genet Test Mol Biomarkers       Date:  2013-08-13

8.  A pharmacogenetics-based warfarin maintenance dosing algorithm from Northern Chinese patients.

Authors:  Jinxing Chen; Liying Shao; Ling Gong; Fang Luo; Jin'e Wang; Yi Shi; Yu Tan; Qianlong Chen; Yu Zhang; Rutai Hui; Yibo Wang
Journal:  PLoS One       Date:  2014-08-15       Impact factor: 3.240

9.  VKORC1 and CYP2C9 Genotype Variations in Relation to Warfarin Dosing in Korean Stroke Patients.

Authors:  Sea Mi Park; Jong-Keuk Lee; Sa Il Chun; Hae In Lee; Sun U Kwon; Dong-Wha Kang; Jong S Kim
Journal:  J Stroke       Date:  2013-05-31       Impact factor: 6.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.